WO1996021468A2 - Interferent chimiquement modifie - Google Patents

Interferent chimiquement modifie Download PDF

Info

Publication number
WO1996021468A2
WO1996021468A2 PCT/US1996/000323 US9600323W WO9621468A2 WO 1996021468 A2 WO1996021468 A2 WO 1996021468A2 US 9600323 W US9600323 W US 9600323W WO 9621468 A2 WO9621468 A2 WO 9621468A2
Authority
WO
WIPO (PCT)
Prior art keywords
ifn
con
interferon
chemically modified
glycosyl
Prior art date
Application number
PCT/US1996/000323
Other languages
English (en)
Other versions
WO1996021468A3 (fr
Inventor
David Collins
Jennifer Lin-Chun Liu
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to BR9607599A priority Critical patent/BR9607599A/pt
Priority to JP8521789A priority patent/JPH10513440A/ja
Priority to AU47518/96A priority patent/AU4751896A/en
Priority to EP96903420A priority patent/EP0804248A2/fr
Publication of WO1996021468A2 publication Critical patent/WO1996021468A2/fr
Publication of WO1996021468A3 publication Critical patent/WO1996021468A3/fr
Priority to MXPA/A/1997/005119A priority patent/MXPA97005119A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La présente invention se rapporte à un interférent de consensus chimiquement modifié possédant au moins un ligand glycosyle, ce ou ces ligands glycosyles étant conjugués à l'interférent de consensus. Des compositions pharmaceutiques contenant cet analogue et des procédés de traitement utilisant les compositions de l'invention sont également décrits.
PCT/US1996/000323 1995-01-13 1996-01-11 Interferent chimiquement modifie WO1996021468A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR9607599A BR9607599A (pt) 1995-01-13 1996-01-11 Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon
JP8521789A JPH10513440A (ja) 1995-01-13 1996-01-11 化学的に修飾したインターフェロン
AU47518/96A AU4751896A (en) 1995-01-13 1996-01-11 Chemically modified interferon
EP96903420A EP0804248A2 (fr) 1995-01-13 1996-01-11 Interferent chimiquement modifie
MXPA/A/1997/005119A MXPA97005119A (en) 1995-01-13 1997-07-08 Modified interferone quimicame

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37247895A 1995-01-13 1995-01-13
US08/372,478 1995-01-13

Publications (2)

Publication Number Publication Date
WO1996021468A2 true WO1996021468A2 (fr) 1996-07-18
WO1996021468A3 WO1996021468A3 (fr) 1996-09-12

Family

ID=23468282

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000323 WO1996021468A2 (fr) 1995-01-13 1996-01-11 Interferent chimiquement modifie

Country Status (9)

Country Link
EP (1) EP0804248A2 (fr)
JP (1) JPH10513440A (fr)
KR (1) KR19980701814A (fr)
AU (1) AU4751896A (fr)
BR (1) BR9607599A (fr)
CA (1) CA2209557A1 (fr)
IL (1) IL116730A0 (fr)
WO (1) WO1996021468A2 (fr)
ZA (1) ZA96206B (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
WO2007044893A2 (fr) 2005-10-11 2007-04-19 Intermune, Inc. Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
WO2008000881A1 (fr) 2006-06-20 2008-01-03 Protech Pharma S.A. Mutéines de l'interféron alpha humain glycosylées et leur procédé d'obtention et d'utilisation
EP2103623A2 (fr) 2005-07-25 2009-09-23 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
WO2011014882A1 (fr) 2009-07-31 2011-02-03 Medtronic, Inc. Administration continue par voie sous-cutanée d'interféron-α à des patients infectés par le virus de l'hépatite c
EP2305313A3 (fr) * 2001-10-10 2011-06-08 BioGeneriX AG Remodelage et glycoconjugation d' interféron alpha (IFNa)
WO2011159930A2 (fr) 2010-06-16 2011-12-22 Medtronic, Inc. Systèmes d'amortissement permettant de stabiliser des médicaments dans des dispositifs de distribution de médicaments
US8404809B2 (en) 2005-05-25 2013-03-26 Novo Nordisk A/S Glycopegylated factor IX
US8632770B2 (en) 2003-12-03 2014-01-21 Novo Nordisk A/S Glycopegylated factor IX
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US9150848B2 (en) 2008-02-27 2015-10-06 Novo Nordisk A/S Conjugated factor VIII molecules
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
WO2008057683A2 (fr) 2006-10-03 2008-05-15 Novo Nordisk A/S Méthodes de purification de conjugués de polypeptides
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022310A1 (fr) * 1991-06-19 1992-12-23 Liver Research Foundation Of Korea Agent medicinal conjugue par asialoglycoproteine
WO1993021229A1 (fr) * 1992-04-15 1993-10-28 Amgen Inc. Procedes et compositions de traitement de maladies par l'interferon, a effets secondaires reduits
EP0589378A2 (fr) * 1992-09-24 1994-03-30 Takeda Chemical Industries, Ltd. Cytokines glycosylées

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087093A (zh) * 1993-09-16 1994-05-25 华西医科大学药学院 肝靶向性的半乳糖基干扰素偶联物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022310A1 (fr) * 1991-06-19 1992-12-23 Liver Research Foundation Of Korea Agent medicinal conjugue par asialoglycoproteine
WO1993021229A1 (fr) * 1992-04-15 1993-10-28 Amgen Inc. Procedes et compositions de traitement de maladies par l'interferon, a effets secondaires reduits
EP0589378A2 (fr) * 1992-09-24 1994-03-30 Takeda Chemical Industries, Ltd. Cytokines glycosylées

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS , vol. 232, no. 1, July 1984, pages 422-426, XP002006624 J.E. LABDON ET AL: "Some species of human lLeukocyte Interferon are glycosylated" *
CHEMICAL ABSTRACTS, vol. 122, no. 12, 20 March 1995 Columbus, Ohio, US; abstract no. 142499f, ZHONG YUGUO ET AL: "Liver-targetable galactosyl interferon conjugate for diagnosis and treatment of liver diseases" page 660; column r; XP002006625 & CN,A,1 087 093 ( HUAXI MEDICAL UNIVERSITY, PHARMACEUTICAL COLLEGE) 25 May 1994 *
PHARMACEUTICAL RESEARCH, vol. 12, no. 12, December 1995, pages 1889-1895, XP002006623 R.W. NIVEN ET AL: "Systemic absorption and activity of recombunant consensus interferons after intratracheal instillation and aerosol administration" *
THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, vol. 32, no. 10, 1984, pages 1091-1098, XP000572708 MIKIO KATAOKA ET AL: "Synthetic neoglycoproteins: a class of reagents for detection of sugar-recognizing substances" cited in the application *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305313A3 (fr) * 2001-10-10 2011-06-08 BioGeneriX AG Remodelage et glycoconjugation d' interféron alpha (IFNa)
EP2298354A3 (fr) * 2001-10-10 2011-06-08 BioGeneriX AG Remodelage et glycoconjugation de Intérferon-beta
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
EP2407470A2 (fr) 2003-10-14 2012-01-18 F. Hoffmann-La Roche Ltd. Acylsulfonamides et acides carboxyliques macrocycliques utilisés en tant qu'inhibiteurs de la réplication du virus de l'hépatite C
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
US8632770B2 (en) 2003-12-03 2014-01-21 Novo Nordisk A/S Glycopegylated factor IX
US10874714B2 (en) 2004-10-29 2020-12-29 89Bio Ltd. Method of treating fibroblast growth factor 21 (FGF-21) deficiency
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8404809B2 (en) 2005-05-25 2013-03-26 Novo Nordisk A/S Glycopegylated factor IX
EP2305697A2 (fr) 2005-07-25 2011-04-06 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EP2103623A2 (fr) 2005-07-25 2009-09-23 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EP2305695A2 (fr) 2005-07-25 2011-04-06 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EP2305696A2 (fr) 2005-07-25 2011-04-06 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
EP2305698A2 (fr) 2005-07-25 2011-04-06 Intermune, Inc. Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
WO2007044893A2 (fr) 2005-10-11 2007-04-19 Intermune, Inc. Composés et méthodes pour l'inhibition de la réplication du virus de l'hépatite c
WO2008000881A1 (fr) 2006-06-20 2008-01-03 Protech Pharma S.A. Mutéines de l'interféron alpha humain glycosylées et leur procédé d'obtention et d'utilisation
US9050304B2 (en) 2007-04-03 2015-06-09 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
US9150848B2 (en) 2008-02-27 2015-10-06 Novo Nordisk A/S Conjugated factor VIII molecules
WO2011014882A1 (fr) 2009-07-31 2011-02-03 Medtronic, Inc. Administration continue par voie sous-cutanée d'interféron-α à des patients infectés par le virus de l'hépatite c
WO2011159930A2 (fr) 2010-06-16 2011-12-22 Medtronic, Inc. Systèmes d'amortissement permettant de stabiliser des médicaments dans des dispositifs de distribution de médicaments

Also Published As

Publication number Publication date
JPH10513440A (ja) 1998-12-22
WO1996021468A3 (fr) 1996-09-12
IL116730A0 (en) 1996-05-14
BR9607599A (pt) 1998-06-09
MX9705119A (es) 1997-10-31
CA2209557A1 (fr) 1996-07-18
ZA96206B (en) 1996-08-19
KR19980701814A (ko) 1998-06-25
AU4751896A (en) 1996-07-31
EP0804248A2 (fr) 1997-11-05

Similar Documents

Publication Publication Date Title
EP0804248A2 (fr) Interferent chimiquement modifie
US5372808A (en) Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US6042822A (en) Interferon polymer conjugates
EP2599503B1 (fr) Conjugués de polymère d'interféron bêta-1A et leurs utilisations
US7262166B2 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
ES2207830T3 (es) Conjugados de polietilenglicol-interferon alfa para la terapia de infecciones.
US20060029573A1 (en) Pegylated interferon alpha-1b
JP5325884B2 (ja) ポリエチレングリコール化インターフェロンα２ｂならびにその製造方法および使用
EP0809996A2 (fr) Conjugués de l'interféron
AU660633B2 (en) Methods and compositions for the treatment of cell proliferation disorders
JP2006519235A (ja) ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
KR20100063108A (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
MX2008014358A (es) Conjugado de polietilenglicol-interferon alfa.
EP0589378A2 (fr) Cytokines glycosylées
MXPA97005119A (en) Modified interferone quimicame
EP2048158B1 (fr) Mutéines de l'interferon alpha humain glycosylees et leur procédé d'obtention et d'utilisation
KR20070110162A (ko) 폴리에틸렌 글리콜-인터페론 알파 접합체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96192521.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2209557

Country of ref document: CA

Ref document number: 2209557

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1996 521789

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/005119

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996903420

Country of ref document: EP

Ref document number: 1019970705211

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1996903420

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970705211

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970705211

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996903420

Country of ref document: EP